Business Wire

EVOLITO-LIMITED

16.4.2024 13:07:29 CEST | Business Wire | Press release

Share
Key Industry Figure Joins Electric Flight Pioneer Evolito to Transform Air Travel

Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics, and battery solutions for aerospace applications, announces the appointment of Marc Holme as CTO, as it prepares for future growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416821458/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Marc Holme, CTO, Evolito (Photo: Business Wire)

Marc Holme joins as CTO to lead the technology development and the future roadmap of the axial-flux e-motor and propulsion product family. He has a 24-year tenure in aviation, most recently at Collins Aerospace where he was Senior Director of Engineering. Holme’s deep technical background has seen him lead multiple aircraft system electrification programs from Airbus A380 to Boeing 787, and many technology acquisition programs.

Commenting on his appointment, Marc Holme, CTO, Evolito said:

“I’m excited to join Evolito to continue the progression towards more sustainable aviation through electrification. The advanced electric motor technology that originated for the automotive market is being adapted and improved by Evolito to enable aerospace applications where weight, efficiency and safety are critical. Combined with its leading motor control electronics and battery technologies, Evolito is well positioned to reach scalable and sustainable electric aviation.”

The new C-suite hire follows a phenomenal year for the company, having received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products in December 2023. Evolito is already working with a number of OEM partners, developing motors and propulsion systems for a variety of eVTOL, Urban Air Mobility and fixed-wing applications, and expects a series of customer test flights later this year.

Dr. Chris Harris, Evolito CEO and co-founder said:

“The whole company is delighted to welcome Marc to the growing Evolito family. I’m extremely proud of what we have created here at Evolito, and our success is a reflection of our hugely talented and dedicated team, driven by a common passion for sustainable mobility. The electrification of flight is one of the most exciting market opportunities of our time, and Evolito’s innovative new technology and ability to scale means we are well positioned to meet this fast-emerging demand.”

Founded in July 2021, Evolito has grown its experienced team from 15 to over 200. It was recently awarded 2nd place in four award categories in the 2023 Best Companies100 Best Place To Work. In July 2022, Evolito acquired and later integrated Electroflight batteries into the business to offer complete propulsion solutions that are fully optimised for future aircraft applications. Amongst other partners, it works with Cranfield Aerospace Solutions who provide motor and inverters for its hydrogen aircraft demonstrator - the Fresson project.

EDITOR’S NOTES

Evolito

http://www.evolito.aero

Evolito is making all-electric flight a reality by offering world-leading electric axial flux motors, motor control units and battery systems for the aerospace market. Evolito’s electric propulsion systems offer the highest power, torque, and energy densities in class and are inherently more robust than alternative technologies – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications. The privately-held company is based in Oxford. Evolito’s investors include B-Flexion and Oxford Science Enterprises (OSE).

Marc Holme, CTO, Evolito boasts 24 years of experience in aviation and a further 5 in automotive. Prior to joining Evolito, Holme was Senior Director Engineering at Collins Aerospace. He has also worked for UTC Aerospace Systems and Goodrich. Holme has a masters in power electronics and drives from The University of Birmingham.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416821458/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye